SCHEMBL30165732

SCHEMBL30165732

Nc1ncnc(N2CCOCC2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 11/20 0.56
PIK3CD O00329 3/20 0.56
PIK3CB P42338 3/20 0.56
PIK3R1 P27986 7/20 0.53
MTOR P42345 7/20 0.53
KDM4E B2RXH2 3/20 0.50
GAA P10253 3/20 0.50
RICTOR Q6R327 1/20 0.48
RPTOR Q8N122 1/20 0.48
MAPKAP1 Q9BPZ7 1/20 0.48
MLST8 Q9BVC4 1/20 0.48
PKM P14618 1/20 0.48
PIK3C2B O00750 1/20 0.47
PIK3CG P48736 1/20 0.47
PIK3C3 Q8NEB9 1/20 0.47
PI4KB Q9UBF8 1/20 0.47
MAP3K12 Q12852 1/20 0.47
KMT2A Q03164 1/20 0.44
ALDH1A1 P00352 2/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL254934 1.00 PIK3CA (0.56) PIK3CAPIK3CDPIK3CBPIK3R1MTOR
SCHEMBL16238117 0.86 PIK3CA (0.56) PIK3CAPIK3CDPIK3CBPIK3R1MTOR
SCHEMBL29582269 0.82 ALDH1A1 (0.41) PIK3CAPIK3CDPIK3CBKMT2AALDH1A1
SCHEMBL28220128 0.82 ALDH1A1 (0.41) PIK3CAPIK3CDPIK3CBKMT2AALDH1A1
SCHEMBL2524177 0.81 MAPK1 (0.58) PIK3CAPIK3CDPIK3CBPIK3R1MTOR
SCHEMBL28256286 0.81 ALDH1A1 (0.44) KDM4EGAAKMT2AALDH1A1GLA
Hydrochloric Acid SCHEMBL28169526 0.79 ALDH1A1 (0.43) KDM4EGAAKMT2AALDH1A1GLA
SCHEMBL2523906 0.79 MAPK1 (0.53) PIK3CAPIK3CDPIK3CBPIK3R1MTOR
SCHEMBL4316997 0.79 TSHR (0.59) PIK3CAPIK3CDPIK3CBPIK3R1MTOR
SCHEMBL1443593 0.78 PIK3CA (0.61) PIK3CAPIK3R1MTORKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 EP claimed
US-20250381202-A1 PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY ZOUNEK ALEX (DE) 2025-12-18 US disclosed
WO-2025118719-A1 SMALL MOLECULE HEPARIN REVERSAL AGENT WITH TRIAZINE SKELETON, AND PREPARATION METHOD THEREFOR AND USE THEREOF 中国药科大学 2025-06-12 WO disclosed
CN-118510516-A Pharmaceutical combination comprising arbelii and PI3K and/or MTOR inhibitors for the treatment of mantle cell lymphoma 德克萨斯州大学系统董事会 2024-08-16 CN disclosed
CN-117624137-A Triazine skeleton small molecule heparin reversal agent and preparation method and application thereof 中国药科大学 2024-03-01 CN disclosed
CN-116745289-A Agonists of free fatty acid receptor 1 and their use in diseases associated with said receptor 奥洛治疗有限公司 2023-09-12 CN disclosed
CN-115697345-A Preparation of 1,3, 5-triazinylbenzimidazoles 梅制药公司 2023-02-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250381202-A1 PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY KIT, CTSL, PAICS PIK3CA 209/4885PIK3CD 269/4885PIK3CB 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.